| scholarly article | Q13442814 |
| P50 | author | Clarence J Peters | Q87841122 |
| P2093 | author name string | Jahrling PB | |
| P2860 | cites work | Lassa fever in Panguma Hospital, Sierra Leone, 1973-6 | Q24674837 |
| Lassa immune serum | Q27485976 | ||
| Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease | Q33467975 | ||
| Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases | Q34209987 | ||
| Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin) | Q36630598 | ||
| Diagnosis of Lassa fever and the isolation and management of patients | Q36630621 | ||
| Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections | Q38616381 | ||
| Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome | Q39579079 | ||
| Immune enhancement of viral infection | Q40132021 | ||
| Pathogenesis of Lassa virus infection in guinea pigs. | Q40598251 | ||
| Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys | Q40828683 | ||
| Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin | Q40839520 | ||
| Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin | Q40861784 | ||
| Lassa fever A study of 23 hospital cases | Q40920544 | ||
| Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus | Q45894483 | ||
| Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin | Q67275640 | ||
| Immunochemical and physiological comparison of horse botulinal antitoxins | Q69109534 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Lassa fever | Q706845 |
| Lassa virus | Q1806636 | ||
| antibody | Q79460 | ||
| P304 | page(s) | 528-533 | |
| P577 | publication date | 1984-05-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain | |
| P478 | volume | 44 |
| Q98502792 | Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity |
| Q26798695 | Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses |
| Q100385866 | Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages |
| Q35847032 | Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection |
| Q38608502 | Arenavirus Quasispecies and Their Biological Implications |
| Q52723914 | Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. |
| Q90068194 | Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein |
| Q56909960 | Current research for a vaccine against Lassa hemorrhagic fever virus |
| Q35076680 | Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques |
| Q33950619 | Diversity among Tacaribe serocomplex viruses (Family Arenaviridae) associated with the southern plains woodrat (Neotoma micropus) |
| Q33383772 | Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys |
| Q33808492 | Effective vaccine for lassa fever |
| Q27320211 | Envelope exchange for the generation of live-attenuated arenavirus vaccines |
| Q39615623 | Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital |
| Q37482648 | Genetic diversity among Bolivian arenaviruses |
| Q24657349 | Genetic diversity between and within the arenavirus species indigenous to western Venezuela |
| Q36694022 | Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever |
| Q40040779 | Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever |
| Q38064284 | Immune responses and Lassa virus infection |
| Q94592124 | In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever |
| Q33652265 | Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers |
| Q34222970 | Lassa serology in natural populations of rodents and horizontal transmission |
| Q37912497 | Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. |
| Q37103536 | Macaque models of human infectious disease |
| Q28602816 | Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits |
| Q36925354 | Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. |
| Q24600257 | Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome |
| Q57476548 | Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever |
| Q38818648 | Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines. |
| Q40091054 | Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates |
| Q34762095 | Passive antibody administration (immediate immunity) as a specific defense against biological weapons |
| Q35014564 | Pathogenesis of Lassa fever in cynomolgus macaques |
| Q38699406 | Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. |
| Q35882397 | Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. |
| Q35207879 | Preventive and therapeutic approaches to viral agents of bioterrorism |
| Q27024953 | Progress in the experimental therapy of severe arenaviral infections |
| Q33568256 | Progress towards recombinant anti-infective antibodies |
| Q91901545 | References |
| Q40811775 | Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development |
| Q40054615 | Structural basis for antibody-mediated neutralization of Lassa virus |
| Q56913187 | The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model |
| Q34489055 | The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field |
| Q36588064 | The search for animal models for Lassa fever vaccine development |
| Q27305228 | Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure |
| Q33542433 | Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases |
| Q34671806 | Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials |
Search more.